A Prospective Study of Human Herpesvirus-6 Infection in Renal Transplantation

Yoshikawa, Tetsushi; Suga, S.; Asano, Yoshizo; Nakashima, Toshihiko; Yazaki, Takehiko; Ono, Yoshinari; Fujita, Tamio; Tsuzuki, Kazuo; Sugiyama, Satoshi; Oshima, Satoshi

doi:10.1097/00007890-199211000-00022

Cited by 93 publications

(52 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the studies about recipients of kidney transplantation conducted in different centers, Okuno et al detected a high rate of increase in HHV-6 antibody titers at a rate of 38% in individuals who had allograft rejection following transplantation [9]. On the other hand, Yoshikawa et al demonstrated that there was an increase in HHV-6 antibody titers at a rate of 55% within the first three months following transplantation in the recipients of kidney transplantation [10]. In the current study, similar results with the control group were obtained in terms of HHV-6 IgG antibody positivity rates in hemodialysis patients who are candidates for renal transplantation.…”

Section: Discussionmentioning

confidence: 99%

Prevalence of Human Herpes Virus 6 (HHV-6) in Patients with Hemodialysis

Tarhan¹,

Yılmaz²

2015

J Infect Dis Ther

View full text Add to dashboard Cite

HHV-6 is the causative agent of exanthema subitum in children. The main modes of transmission of HHV-6 are body secretions such as infected saliva but it can be transmitted with blood and blood products that are infected with the virus. Therefore, it is thought that the immunocompromised hemodialysis patients who had multiple blood transfusions due to various reasons, and who collectively use devices such as hemodialysis machines are at risk for HHV-6 infection. The present study aimed to determine the incidence of HHV-6 infection in hemodialysis patients. Twenty-five healthy individuals that were matched with 25 hemodialysis patients in terms of gender and age were included in the study. The IgM and IgG sero-prevalence in the patient and control groups were investigated with the indirect fluorescence antibody method and HHV-6 DNA prevalence and the determination of variant types (variant A and variant B) were investigated with the PCR-RFLP molecular method. HHV-6 IgG and HHV-6 IgM antibody positivity ratios in the patient and control groups were 76% and 20% respectively. Out of 50 serum samples of hemodialysis patients and healthy individuals, HHV-6 DNA was positive in seven of 25 samples of hemodialysis patients (28%) and it was positive in eight of 25 samples of the control group (32%). Variant analysis was performed with the PCR-RFLP method in HHV-6 DNA positive hemodialysis patients and control patients. At the end of the analysis, while variant A was not detected in the patient and control groups, variant B was detected in a total of 15 individuals, including seven patients in the hemodialysis patient group and eight patients in the control group. In conclusion, the researchers believe that there is a need for controlled studies including more samples to determine the clinical importance of HHV-6 DNA and HHV-6 variants in hemodialysis patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Prevalence of Human Herpes Virus 6 (HHV-6) in Patients with Hemodialysis

Tarhan¹,

Yılmaz²

2015

J Infect Dis Ther

View full text Add to dashboard Cite

show abstract

“…The precise frequency of such episodes of viral reactivation is contingent upon several things, including the type of transplant and, likely, the degree of immunosuppression. Human herpesvirus-6 has been implicated as a cause of disease in renal transplant recipients (Asano et al, 1989b;Morris et al, 1989;Gudnason et al, 1991;Yoshikawa et al, 1992c), bone marrow transplant recipients (Asano et al, 1991b;Yoshikawa et al, 1991;Knox and Carrigan, 1992;Rosenfeld et al, 1995;Knox and Carrigan, 1996b) and liver transplant recipients (Ward et al, 1989;Sutherland et al, 1991;Singh et al, 1995). Neurologic disorders attributable to HHV-6 have been reported in bone marrow (Yanagihara et al, 1995) and liver transplant patients (Ward et al, 1989;Sutherland et al, 1991;Singh et al, 1995) and include seizures, encephalopathy and encephalitis.…”

Section: Infection In Immunocompromised Patientsmentioning

confidence: 99%

Human Herpesvirus-6: Neurologic Implications of a Newly-Described Viral Pathogen

Kimberlin

Whitley

1998

J Neurovirol

View full text Add to dashboard Cite

Discovered only 12 years ago, human herpesvirus-6 (HHV-6) has been associated with central nervous system (CNS) ®ndings such as febrile seizures, encephalitis, meningitis, and possibly multiple sclerosis. These manifestations have been reported in both immunocompetent and immunocompromised individuals. The applications of such sophisticated laboratory tools as polymerase chain reaction, in situ hybridization, immunohistochemical staining, and representational difference analysis have expanded knowledge of the spectrum of CNS disease attributable to HHV-6 while delineating pathogenic mechanisms of both primary HHV-6 infection and reactivation from latency. This article reviews existing knowledge of the CNS manifestations of HHV-6, focusing on both clinical aspects of HHV-6 infection and its pathogenesis on neurologic diseases.

show abstract

“…other than that evidence of viral replication can be found in approximately half of transplant patients. (Since the clinical impact of HHV-6 in transplant patients is currently unclear [8], lhis herpesvirus will not be considered further in this review.) Herpesviruses are highly cell-associated, meaning spread of virus between individuals requires either intimate mucosal contact or lhe physical transfer of the virus (in this case in latent form) via a leukocytecontaining blood product or an allograft.…”

Section: Herpesvirus Infectionmentioning

confidence: 99%

Control of Herpesvirus Infection in Organ Transplant Recipients

Tolkoff-Rubin¹,

Rubin²

1993

Canadian Journal of Infectious Diseases and Medical Microbiolog

View full text Add to dashboard Cite

The most important causes of infectious disease morbidity and mortality in organ transplant recipients are the herpesviruses, particularly cytomegalovirus (CMV) and Epstein-Barrvirus (EBV). Because of their properties of latency, cell association, and potential oncogenicity, they are particularly well suited to causing disease in the transplant patient. Antilymphocyte antibody therapies are potent reactivators of these viruses, and cyclosporine, by inhibiting the critical host defense (virus specific cytotoxic T cells) in a dose-dependent fashion, amplifies the extent and effects of the viral replication. This in turn is translated into clinical disease: fever; pneumonia; gastrointestinal ulcerations; broad-based suppression of host defences leading to opportunistic superinfection and, perhaps, allograft injury in the case of CMV; and B cell lymphoproliferative disease in the case of EBV. New approaches to controlling these viruses in which pre-emptive therapy is linked to immunosuppressive therapy, and new diagnostic techniques for viral monitoring, hold promise for limiting clinical disease due to these viruses.

show abstract

A Prospective Study of Human Herpesvirus-6 Infection in Renal Transplantation

Cited by 93 publications

References 0 publications

Prevalence of Human Herpes Virus 6 (HHV-6) in Patients with Hemodialysis

Prevalence of Human Herpes Virus 6 (HHV-6) in Patients with Hemodialysis

Human Herpesvirus-6: Neurologic Implications of a Newly-Described Viral Pathogen

Control of Herpesvirus Infection in Organ Transplant Recipients

Contact Info

Product

Resources

About